Parkside Financial Bank & Trust Makes New $27,000 Investment in Fractyl Health, Inc. (NASDAQ:GUTS)

Parkside Financial Bank & Trust acquired a new position in shares of Fractyl Health, Inc. (NASDAQ:GUTS) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 13,333 shares of the company’s stock, valued at approximately $27,000.

Several other hedge funds also recently modified their holdings of GUTS. Jane Street Group LLC acquired a new position in Fractyl Health during the third quarter valued at approximately $25,000. JPMorgan Chase & Co. raised its stake in shares of Fractyl Health by 335.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock worth $37,000 after purchasing an additional 11,406 shares in the last quarter. HighTower Advisors LLC acquired a new stake in shares of Fractyl Health in the 3rd quarter valued at approximately $38,000. Beta Wealth Group Inc. acquired a new stake in shares of Fractyl Health in the 3rd quarter valued at approximately $44,000. Finally, Stoneridge Investment Partners LLC bought a new position in shares of Fractyl Health in the fourth quarter valued at $45,000.

Insider Buying and Selling at Fractyl Health

In other news, CEO Harith Rajagopalan sold 90,972 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $1.82, for a total value of $165,569.04. Following the transaction, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at $894,218.78. This represents a 15.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jay David Caplan sold 22,346 shares of Fractyl Health stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $1.81, for a total transaction of $40,446.26. Following the sale, the insider now directly owns 153,544 shares of the company’s stock, valued at $277,914.64. The trade was a 12.70 % decrease in their position. The disclosure for this sale can be found here.

Fractyl Health Stock Performance

Shares of NASDAQ:GUTS opened at $1.56 on Tuesday. Fractyl Health, Inc. has a 52-week low of $1.37 and a 52-week high of $10.50. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. The company has a market capitalization of $75.03 million and a P/E ratio of -0.13. The company has a 50-day simple moving average of $1.77 and a 200 day simple moving average of $2.28.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). Sell-side analysts forecast that Fractyl Health, Inc. will post -1.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley dropped their price target on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.